ALNY

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Alnylam Pharmaceuticals Inc

NASDAQ | ALNY

458.12

USD

$0.00

(

0.00%

)

At Close (As of Dec 5, 2025)

$61.48B

Market Cap

1661.93

P/E Ratio

0.28

EPS

$495.55

52 Week High

$205.87

52 Week Low

HEALTHCARE

Sector

ALNY Chart

Recent Chart
Price Action

ALNY Technicals

Tags:

ALNY Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $1.9B
Total Revenue $2.2B
Cost Of Revenue $323M
Costof Goods And Services Sold $323M
Operating Income -$177M
Selling General And Administrative $976M
Research And Development $1.1B
Operating Expenses $2.1B
Investment Income Net -
Net Interest Income -$20M
Interest Income $122M
Interest Expense $142M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $57M
Income Before Tax -$377M
Income Tax Expense -$99M
Interest And Debt Expense -
Net Income From Continuing Operations -$278M
Comprehensive Income Net Of Tax -
Ebit -$236M
Ebitda -$179M
Net Income -$278M

Revenue & Profitability

Earnings Performance

ALNY Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $4.2B
Total Current Assets $3.3B
Cash And Cash Equivalents At Carrying Value $966M
Cash And Short Term Investments $966M
Inventory $79M
Current Net Receivables $405M
Total Non Current Assets $945M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $1.7B
Other Current Assets $117M
Other Non Current Assets -
Total Liabilities $4.2B
Total Current Liabilities $1.2B
Current Accounts Payable $88M
Deferred Revenue -
Current Debt -
Short Term Debt $155M
Total Non Current Liabilities $3B
Capital Lease Obligations $271M
Long Term Debt $1B
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $2.7B
Other Current Liabilities $887M
Other Non Current Liabilities $1.7B
Total Shareholder Equity $67M
Treasury Stock -
Retained Earnings -$7.3B
Common Stock $1.3M
Common Stock Shares Outstanding $128M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$8.3M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $57M
Capital Expenditures $34M
Change In Receivables -
Change In Inventory $14M
Profit Loss -
Cashflow From Investment -$117M
Cashflow From Financing $294M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$278M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $1.9B
Total Revenue $2.2B
Cost Of Revenue $323M
Costof Goods And Services Sold $323M
Operating Income -$177M
Selling General And Administrative $976M
Research And Development $1.1B
Operating Expenses $2.1B
Investment Income Net -
Net Interest Income -$20M
Interest Income $122M
Interest Expense $142M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $57M
Income Before Tax -$377M
Income Tax Expense -$99M
Interest And Debt Expense -
Net Income From Continuing Operations -$278M
Comprehensive Income Net Of Tax -
Ebit -$236M
Ebitda -$179M
Net Income -$278M

ALNY News

ALNY Profile

Alnylam Pharmaceuticals Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Alnylam Pharmaceuticals, Inc. is a pioneering biopharmaceutical company headquartered in Cambridge, Massachusetts, specializing in the development and commercialization of transformative RNA interference (RNAi) therapeutics aimed at addressing genetic diseases. The company boasts a robust pipeline of innovative RNAi-based therapies and has made significant strides in the market, including the successful launch of its first commercial product. With a steadfast commitment to scientific excellence and the advancement of medicine, Alnylam is positioned as a leader in the biopharmaceutical sector, striving to redefine treatment paradigms for both rare and prevalent diseases.

PAVS
+16.19%
$0.03
LPTX
+368.57%
$2.05
WBD
+6.27%
$26.08
IRBT
+21.78%
$3.69
NVDA
-0.52%
$182.41
INHD
+10.95%
$0.15
SOFI
-6.14%
$27.78
NFLX
-2.88%
$100.24
ASST
-7.79%
$0.90
TDIC
+40.20%
$0.39
BYND
-1.61%
$1.22
INTC
+2.24%
$41.41
TNFA
+48.17%
$6.92
PLUG
-1.34%
$2.20
WHLR
+97.83%
$6.41
ONDS
-1.30%
$9.07
IPG
-1.95%
$24.57
VALE
-4.86%
$12.90
AXDX
-61.36%
$0.03
BBD
-8.95%
$3.30
VHAI
+100.00%
$0.00
AAL
+3.27%
$14.81
TSLA
+0.10%
$455.00
DBRG
+45.52%
$14.14
ABEV
-4.45%
$2.46
ITUB
-6.68%
$7.53
RGTI
-6.48%
$28.11
ADAP
-15.14%
$0.05
DNN
-3.34%
$2.74
YGMZ
+24.25%
$0.07
HPE
+1.85%
$23.32
PFE
+1.24%
$26.02
BMNR
-5.91%
$34.16
BITF
-5.80%
$2.92
RR
-2.83%
$4.46
SOND
-23.45%
$0.12
F
-0.64%
$13.05
GRAB
-2.07%
$5.19
PBR
-5.93%
$12.11
RIVN
-0.60%
$17.95
NFE
+12.14%
$1.57
KEY
+0.73%
$19.25
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
QBTS
-6.02%
$27.00
JFBR
-32.00%
$1.70
BMNU
-12.17%
$8.18
NIO
+0.79%
$5.05
ACHR
-3.72%
$8.61
SRM
+53.27%
$10.30
BAC
-0.48%
$53.90
KITT
-4.27%
$1.12
AMD
+0.92%
$217.97
TWOH
+9.09%
$0.00
AMZN
+0.18%
$229.53
CLSK
-8.74%
$13.71
PLTR
+2.15%
$181.76
AKAN
-0.87%
$0.93
DVLT
-8.33%
$1.70
MARA
-4.58%
$11.87
GGB
-6.08%
$3.47
CHR
+1.50%
$0.04
BTG
-0.21%
$4.55
WLGS
-5.57%
$0.04
QCLS
-1.01%
$6.85
MTSR
-0.35%
$70.50
STAI
+32.35%
$0.30
SNAP
+1.48%
$7.87
GOOGL
+1.14%
$321.27
APLD
+0.25%
$31.22
PLTD
-2.10%
$6.52
SMR
-6.41%
$21.38
VZ
+1.04%
$41.69
HBAN
-1.16%
$16.90
CIFR
-2.77%
$19.28
AIIO
-6.92%
$0.60
CGC
-4.95%
$1.15
TGL
+276.44%
$25.44
BTBT
-6.72%
$2.22
AAPL
-0.62%
$278.95
ORCL
+1.52%
$217.59
AFMD
-34.94%
$0.18
IREN
-2.99%
$45.06
IXHL
-4.63%
$0.45
WMT
+0.23%
$115.11
AGNC
+1.23%
$10.62
MSFT
+0.48%
$483.16
IONZ
+7.09%
$3.32
AVGO
+2.41%
$390.24
HIMS
-2.02%
$39.21
PMCB
+0.82%
$1.22
GPUS
-5.01%
$0.27
KOS
+7.94%
$1.15
SATS
+9.80%
$81.80
MRVL
+0.73%
$98.91
META
+1.79%
$673.42
MU
+4.66%
$237.22
WULF
-3.97%
$14.50
QUBT
-5.44%
$12.84
PAVS
+16.19%
$0.03
LPTX
+368.57%
$2.05
WBD
+6.27%
$26.08
IRBT
+21.78%
$3.69
NVDA
-0.52%
$182.41
INHD
+10.95%
$0.15
SOFI
-6.14%
$27.78
NFLX
-2.88%
$100.24
ASST
-7.79%
$0.90
TDIC
+40.20%
$0.39
BYND
-1.61%
$1.22
INTC
+2.24%
$41.41
TNFA
+48.17%
$6.92
PLUG
-1.34%
$2.20
WHLR
+97.83%
$6.41
ONDS
-1.30%
$9.07
IPG
-1.95%
$24.57
VALE
-4.86%
$12.90
AXDX
-61.36%
$0.03
BBD
-8.95%
$3.30
VHAI
+100.00%
$0.00
AAL
+3.27%
$14.81
TSLA
+0.10%
$455.00
DBRG
+45.52%
$14.14
ABEV
-4.45%
$2.46
ITUB
-6.68%
$7.53
RGTI
-6.48%
$28.11
ADAP
-15.14%
$0.05
DNN
-3.34%
$2.74
YGMZ
+24.25%
$0.07
HPE
+1.85%
$23.32
PFE
+1.24%
$26.02
BMNR
-5.91%
$34.16
BITF
-5.80%
$2.92
RR
-2.83%
$4.46
SOND
-23.45%
$0.12
F
-0.64%
$13.05
GRAB
-2.07%
$5.19
PBR
-5.93%
$12.11
RIVN
-0.60%
$17.95
NFE
+12.14%
$1.57
KEY
+0.73%
$19.25
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
QBTS
-6.02%
$27.00
JFBR
-32.00%
$1.70
BMNU
-12.17%
$8.18
NIO
+0.79%
$5.05
ACHR
-3.72%
$8.61
SRM
+53.27%
$10.30
BAC
-0.48%
$53.90
KITT
-4.27%
$1.12
AMD
+0.92%
$217.97
TWOH
+9.09%
$0.00
AMZN
+0.18%
$229.53
CLSK
-8.74%
$13.71
PLTR
+2.15%
$181.76
AKAN
-0.87%
$0.93
DVLT
-8.33%
$1.70
MARA
-4.58%
$11.87
GGB
-6.08%
$3.47
CHR
+1.50%
$0.04
BTG
-0.21%
$4.55
WLGS
-5.57%
$0.04
QCLS
-1.01%
$6.85
MTSR
-0.35%
$70.50
STAI
+32.35%
$0.30
SNAP
+1.48%
$7.87
GOOGL
+1.14%
$321.27
APLD
+0.25%
$31.22
PLTD
-2.10%
$6.52
SMR
-6.41%
$21.38
VZ
+1.04%
$41.69
HBAN
-1.16%
$16.90
CIFR
-2.77%
$19.28
AIIO
-6.92%
$0.60
CGC
-4.95%
$1.15
TGL
+276.44%
$25.44
BTBT
-6.72%
$2.22
AAPL
-0.62%
$278.95
ORCL
+1.52%
$217.59
AFMD
-34.94%
$0.18
IREN
-2.99%
$45.06
IXHL
-4.63%
$0.45
WMT
+0.23%
$115.11
AGNC
+1.23%
$10.62
MSFT
+0.48%
$483.16
IONZ
+7.09%
$3.32
AVGO
+2.41%
$390.24
HIMS
-2.02%
$39.21
PMCB
+0.82%
$1.22
GPUS
-5.01%
$0.27
KOS
+7.94%
$1.15
SATS
+9.80%
$81.80
MRVL
+0.73%
$98.91
META
+1.79%
$673.42
MU
+4.66%
$237.22
WULF
-3.97%
$14.50
QUBT
-5.44%
$12.84
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.